FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1201-1214 March 27, 2003 Number 13 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Schwartz, R. S. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the cause.

Methods We treated 11 patients with the hypereosinophilic syndrome with imatinib and identified the molecular basis for the response.

Results Nine of the 11 patients treated with imatinib had responses lasting more than three months in which the eosinophil count returned to normal. One such patient had a complex chromosomal abnormality, leading to the identification of a fusion of the Fip1-like 1 (FIP1L1) gene to the PDGFR (PDGFRA) gene generated by an interstitial deletion on chromosome 4q12. FIP1L1-PDGFR is a constitutively activated tyrosine kinase that transforms hematopoietic cells and is inhibited by imatinib (50 percent inhibitory concentration, 3.2 nM). The FIP1L1-PDGFRA fusion gene was subsequently detected in 9 of 16 patients with the syndrome and in 5 of the 9 patients with responses to imatinib that lasted more than three months. Relapse in one patient correlated with the appearance of a T674I mutation in PDGFRA that confers resistance to imatinib.

Conclusions The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase — FIP1L1-PDGFR — that is a consequence of an interstitial chromosomal deletion. The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFR is the target of imatinib. Our data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.

Source Information

From Brigham and Women's Hospital and Harvard Medical School, Boston (J. Cools, E.H.S., J.K., J. Clark, D.G.G.); the Dana–Farber Cancer Institute, Boston (D.J.D., J. Clark, I.G., J.D.G., R.S., D.G.G.); Stanford University School of Medicine, Stanford, Calif. (J.G., J.M., S.L.S., S.E.C.); Women and Infants Hospital, Brown University School of Medicine, Providence, R.I., and Westerly Hospital, Westerly, R.I. (R.D.L.); M.D. Anderson Cancer Center, Houston (J. Cortes, H.K.); the Wessex Regional Genetics Laboratory, Salisbury, United Kingdom (N.C.P.C.); Mayo Clinic, Rochester, Minn. (A.T.); National Jewish Medical and Research Center, Denver (R.A.); Tulane University School of Medicine, New Orleans (J.S.); Yale University School of Medicine, New Haven, Conn. (M.R.); University Hospital Leuven, Leuven, Belgium (P.V., G.V., M.B.); Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium (J. Cools, P.M.); Center for Human Genetics, Leuven, Belgium (I.W.); and Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston (D.G.G.).

Drs. Cools and DeAngelo contributed equally to this article.

Address reprint requests to Dr. Gilliland at the Harvard Institutes of Medicine, 4 Blackfan Cir., Rm. 418, Boston, MA 02115 (gilliland{at}hihg.med.harvard.edu) or to Dr. Stone at the Dana–Farber Cancer Institute, 44 Binney St., Boston, MA 02115 (rstone{at}partners.org).

Full Text of this Article

Related Letters:

Hypereosinophilic Syndrome
Roufosse F. E., Goldman M., Cogan E., Gilliland D. G., Stone R. M., Coutre S. E.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:2687, Jun 26, 2003. Correspondence

This article has been cited by other articles:

• McDermott, U., Settleman, J. (2009). Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. JCO 27: 5650-5659 [Abstract] [Full Text]  
• Klion, A. D. (2009). How I treat hypereosinophilic syndromes. Blood 114: 3736-3741 [Abstract] [Full Text]  
• Wolpin, B. M., Weller, P. F., Katz, J. T., Levy, B. D., Loscalzo, J. (2009). The Writing on the Wall. NEJM 361: 1387-1392 [Full Text]  
• Lierman, E., Van Miegroet, H., Beullens, E., Cools, J. (2009). Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen. haematol 94: 1440-1444 [Abstract] [Full Text]  
• Ravoet, M., Sibille, C., Gu, C., Libin, M., Haibe-Kains, B., Sotiriou, C., Goldman, M., Roufosse, F., Willard-Gallo, K. (2009). Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood 114: 2969-2983 [Abstract] [Full Text]  
• Roufosse, F. (2009). Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. haematol 94: 1188-1193 [Full Text]  
• Helbig, G., Wieczorkiewicz, A., Dziaczkowska-Suszek, J., Majewski, M., Kyrcz-Krzemien, S. (2009). T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. haematol 94: 1236-1241 [Abstract] [Full Text]  
• Thiele, J. (2009). Philadelphia Chromosome-Negative Chronic Myeloproliferative Disease. Am J Clin Pathol 132: 261-280 [Abstract] [Full Text]  
• Toffalini, F., Kallin, A., Vandenberghe, P., Pierre, P., Michaux, L., Cools, J., Demoulin, J.-B. (2009). The fusion proteins TEL-PDGFR{beta} and FIP1L1-PDGFR{alpha} escape ubiquitination and degradation. haematol 94: 1085-1093 [Abstract] [Full Text]  
• Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellstrom-Lindberg, E., Tefferi, A., Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951 [Abstract] [Full Text]  
• Paulsson, J., Sjoblom, T., Micke, P., Ponten, F., Landberg, G., Heldin, C.-H., Bergh, J., Brennan, D. J., Jirstrom, K., Ostman, A. (2009). Prognostic Significance of Stromal Platelet-Derived Growth Factor {beta}-Receptor Expression in Human Breast Cancer. Am. J. Pathol. 175: 334-341 [Abstract] [Full Text]  
• Minagawa, K., Katayama, Y., Nishikawa, S., Yamamoto, K., Sada, A., Okamura, A., Shimoyama, M., Matsui, T. (2009). Inhibition of G1 to S Phase Progression by a Novel Zinc Finger Protein P58TFL at P-bodies. Mol Cancer Res 7: 880-889 [Abstract] [Full Text]  
• Kaye, F. J. (2009). Mutation-associated fusion cancer genes in solid tumors. Molecular Cancer Therapeutics 8: 1399-1408 [Abstract] [Full Text]  
• McDermott, U., Ames, R. Y., Iafrate, A. J., Maheswaran, S., Stubbs, H., Greninger, P., McCutcheon, K., Milano, R., Tam, A., Lee, D. Y., Lucien, L., Brannigan, B. W., Ulkus, L. E., Ma, X.-J., Erlander, M. G., Haber, D. A., Sharma, S. V., Settleman, J. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-{alpha} Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Res. 69: 3937-3946 [Abstract] [Full Text]  
• Vannucchi, A. M., Guglielmelli, P., Tefferi, A. (2009). Advances in Understanding and Management of Myeloproliferative Neoplasms. CA Cancer J Clin 59: 171-191 [Abstract] [Full Text]  
• O'Sullivan, S., Horne, A., Wattie, D., Porteous, F., Callon, K., Gamble, G., Ebeling, P., Browett, P., Grey, A. (2009). Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib. J. Clin. Endocrinol. Metab. 94: 1131-1136 [Abstract] [Full Text]  
• von Bubnoff, N., Engh, R. A., Aberg, E., Sanger, J., Peschel, C., Duyster, J. (2009). FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro. Cancer Res. 69: 3032-3041 [Abstract] [Full Text]  
• Fukushima, K., Matsumura, I., Ezoe, S., Tokunaga, M., Yasumi, M., Satoh, Y., Shibayama, H., Tanaka, H., Iwama, A., Kanakura, Y. (2009). FIP1L1-PDGFR{alpha} Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor Cells. J. Biol. Chem. 284: 7719-7732 [Abstract] [Full Text]  
• Cornejo, M. G., Kharas, M. G., Werneck, M. B., Bras, S. L., Moore, S. A., Ball, B., Beylot-Barry, M., Rodig, S. J., Aster, J. C., Lee, B. H., Cantor, H., Merlio, J.-P., Gilliland, D. G., Mercher, T. (2009). Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 113: 2746-2754 [Abstract] [Full Text]  
• Seeliger, M. A., Ranjitkar, P., Kasap, C., Shan, Y., Shaw, D. E., Shah, N. P., Kuriyan, J., Maly, D. J. (2009). Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations. Cancer Res. 69: 2384-2392 [Abstract] [Full Text]  
• Negri, T., Pavan, G. M., Virdis, E., Greco, A., Fermeglia, M., Sandri, M., Pricl, S., Pierotti, M. A., Pilotti, S., Tamborini, E. (2009). T670X KIT Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense. JNCI J Natl Cancer Inst 101: 194-204 [Abstract] [Full Text]  
• Mori, Y., Iwasaki, H., Kohno, K., Yoshimoto, G., Kikushige, Y., Okeda, A., Uike, N., Niiro, H., Takenaka, K., Nagafuji, K., Miyamoto, T., Harada, M., Takatsu, K., Akashi, K. (2009). Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. JEM 206: 183-193 [Abstract] [Full Text]  
• Verstovsek, S., Tefferi, A., Kantarjian, H., Manshouri, T., Luthra, R., Pardanani, A., Quintas-Cardama, A., Ravandi, F., Ault, P., Bueso-Ramos, C., Cortes, J. E. (2009). Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia. Clin. Cancer Res. 15: 368-373 [Abstract] [Full Text]  
• Druker, B. J. (2008). Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808-4817 [Abstract] [Full Text]  
• Yamada, Y., Sanchez-Aguilera, A., Brandt, E. B., McBride, M., Al-Moamen, N. J. H., Finkelman, F. D., Williams, D. A., Cancelas, J. A., Rothenberg, M. E. (2008). FIP1L1/PDGFR{alpha} synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood 112: 2500-2507 [Abstract] [Full Text]  
• Kondo, T., Mori, A., Darmanin, S., Hashino, S., Tanaka, J., Asaka, M. (2008). The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. haematol 93: 1414-1416 [Full Text]  
• Frohling, S., Dohner, H. (2008). Chromosomal Abnormalities in Cancer. NEJM 359: 722-734 [Full Text]  
• Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., Dobrzanski, P. (2008). Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671 [Abstract] [Full Text]  
• Andrae, J., Gallini, R., Betsholtz, C. (2008). Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22: 1276-1312 [Abstract] [Full Text]  
• Engelman, J. A., Janne, P. A. (2008). Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 2895-2899 [Abstract] [Full Text]  
• Nimer, S. D. (2008). Myelodysplastic syndromes. Blood 111: 4841-4851 [Abstract] [Full Text]  
• Nishioka, C., Ikezoe, T., Yang, J., Miwa, A., Tasaka, T., Kuwayama, Y., Togitani, K., Koeffler, H. P., Yokoyama, A. (2008). Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 111: 5086-5092 [Abstract] [Full Text]  
• Pierce, A., Unwin, R. D., Evans, C. A., Griffiths, S., Carney, L., Zhang, L., Jaworska, E., Lee, C.-F., Blinco, D., Okoniewski, M. J., Miller, C. J., Bitton, D. A., Spooncer, E., Whetton, A. D. (2008). Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases. Mol. Cell. Proteomics 7: 853-863 [Abstract] [Full Text]  
• Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., McKinley, A., Supple, S. G., Seymour, J., Di Scala, L., van Oosterom, A., Herrmann, R., Nikolova, Z., McArthur, a. G., for the Imatinib Target Exploration Consortium Stu, (2008). Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases. Clin. Cancer Res. 14: 2717-2725 [Abstract] [Full Text]  
• Loriaux, M. M., Levine, R. L., Tyner, J. W., Frohling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., Bernard, O. A., Griffin, J. D., Stone, R. M., Lee, B., Meyerson, M., Heinrich, M. C., Deininger, M. W., Gilliland, D. G., Druker, B. J. (2008). High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111: 4788-4796 [Abstract] [Full Text]  
• Zota, V., Miron, P. M., Woda, B. A., Raza, A., Wang, S. A. (2008). Eosinophilia With FIP1L1-PDGFRA Fusion in a Patient With Chronic Myelomonocytic Leukemia. JCO 26: 2040-2041 [Full Text]  
• Wechsler, M. E. (2008). Combating the Eosinophil with Anti-Interleukin-5 Therapy. NEJM 358: 1293-1294 [Full Text]  
• Gibbons, J., Egorin, M. J., Ramanathan, R. K., Fu, P., Mulkerin, D. L., Shibata, S., Takimoto, C. H.M., Mani, S., LoRusso, P. A., Grem, J. L., Pavlick, A., Lenz, H.-J., Flick, S. M., Reynolds, S., Lagattuta, T. F., Parise, R. A., Wang, Y., Murgo, A. J., Ivy, S. P., Remick, S. C. (2008). Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. JCO 26: 570-576 [Abstract] [Full Text]  
• Page, K. R., Zenilman, J. (2008). Eosinophilia in a Patient From South America. JAMA 299: 437-444 [Abstract] [Full Text]  
• Tefferi, A., Verstovsek, S., Pardanani, A. (2008). How we diagnose and treat WHO-defined systemic mastocytosis in adults. haematol 93: 6-9 [Full Text]  
• Lahortiga, I., Akin, C., Cools, J., Wilson, T. M., Mentens, N., Arthur, D. C., Maric, I., Noel, P., Kocabas, C., Marynen, P., Lessin, L. S., Wlodarska, I., Robyn, J., Metcalfe, D. D. (2008). Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. haematol 93: 49-56 [Abstract] [Full Text]  
• Azuma, M., Nishioka, Y., Aono, Y., Inayama, M., Makino, H., Kishi, J., Shono, M., Kinoshita, K., Uehara, H., Ogushi, F., Izumi, K., Sone, S. (2007). Role of {alpha}1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice. Am. J. Respir. Crit. Care Med. 176: 1243-1250 [Abstract] [Full Text]  
• Chase, A., Grand, F. H., Cross, N. C. P. (2007). Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110: 3729-3734 [Abstract] [Full Text]  
• Klion, A. D., Robyn, J., Maric, I., Fu, W., Schmid, L., Lemery, S., Noel, P., Law, M. A., Hartsell, M., Talar-Williams, C., Fay, M. P., Dunbar, C. E., Nutman, T. B. (2007). Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 110: 3552-3556 [Abstract] [Full Text]  
• Reiter, A., Grimwade, D., Cross, N. C.P. (2007). Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. haematol 92: 1153-1158 [Full Text]  
• Baccarani, M., Cilloni, D., Rondoni, M., Ottaviani, E., Messa, F., Merante, S., Tiribelli, M., Buccisano, F., Testoni, N., Gottardi, E., de Vivo, A., Giugliano, E., Iacobucci, I., Paolini, S., Soverini, S., Rosti, G., Rancati, F., Astolfi, C., Pane, F., Saglio, G., Martinelli, G. (2007). The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR{alpha}-positive hypereosinophilic syndrome. Results of a multicenter prospective study. haematol 92: 1173-1179 [Abstract] [Full Text]  
• Taverna, J. A., Lerner, A., Goldberg, L., Werth, S., Demierre, M.-F. (2007). Infliximab as a Therapy for Idiopathic Hypereosinophilic Syndrome. Arch Dermatol 143: 1110-1112 [Full Text]  
• Pao, W., Ladanyi, M. (2007). Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method. Clin. Cancer Res. 13: 4954-4955 [Full Text]  
• Reiterer, G., Yen, A. (2007). Platelet-Derived Growth Factor Receptor Regulates Myeloid and Monocytic Differentiation of HL-60 Cells. Cancer Res. 67: 7765-7772 [Abstract] [Full Text]  
• Pellagatti, A., Jadersten, M., Forsblom, A.-M., Cattan, H., Christensson, B., Emanuelsson, E. K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., Wainscoat, J. S., Boultwood, J., Hellstrom-Lindberg, E. (2007). Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc. Natl. Acad. Sci. USA 104: 11406-11411 [Abstract] [Full Text]  
• Wiencke, J. K., Zheng, S., Jelluma, N., Tihan, T., Vandenberg, S., Tamguney, T., Baumber, R., Parsons, R., Lamborn, K. R., Berger, M. S., Wrensch, M. R., Haas-Kogan, D. A., Stokoe, D. (2007). Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol Duke 9: 271-279 [Abstract] [Full Text]  
• Lambert, F., Heimann, P., Herens, C., Chariot, A., Bours, V. (2007). A Case of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia with a Rare FIP1L1 Breakpoint. J. Mol. Diagn. 9: 414-419 [Abstract] [Full Text]  
• Weisberg, E., Kung, A. L., Wright, R. D., Moreno, D., Catley, L., Ray, A., Zawel, L., Tran, M., Cools, J., Gilliland, G., Mitsiades, C., McMillin, D. W., Jiang, J., Hall-Meyers, E., Griffin, J. D. (2007). Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics 6: 1951-1961 [Abstract] [Full Text]  
• Gu, T.-l., Mercher, T., Tyner, J. W., Goss, V. L., Walters, D. K., Cornejo, M. G., Reeves, C., Popova, L., Lee, K., Heinrich, M. C., Rush, J., Daibata, M., Miyoshi, I., Gilliland, D. G., Druker, B. J., Polakiewicz, R. D. (2007). A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 110: 323-333 [Abstract] [Full Text]  
• Utikal, J., Ugurel, S., Kurzen, H., Erben, P., Reiter, A., Hochhaus, A., Nebe, T., Hildenbrand, R., Haberkorn, U., Goerdt, S., Schadendorf, D. (2007). Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses. Arch Dermatol 143: 736-740 [Abstract] [Full Text]  
• Guida, T., Anaganti, S., Provitera, L., Gedrich, R., Sullivan, E., Wilhelm, S. M., Santoro, M., Carlomagno, F. (2007). Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor {beta} Gatekeeper Mutants. Clin. Cancer Res. 13: 3363-3369 [Abstract] [Full Text]  
• Jovanovic, J. V., Score, J., Waghorn, K., Cilloni, D., Gottardi, E., Metzgeroth, G., Erben, P., Popp, H., Walz, C., Hochhaus, A., Roche-Lestienne, C., Preudhomme, C., Solomon, E., Apperley, J., Rondoni, M., Ottaviani, E., Martinelli, G., Brito-Babapulle, F., Saglio, G., Hehlmann, R., Cross, N. C. P., Reiter, A., Grimwade, D., on behalf of the European LeukemiaNet, (2007). Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 109: 4635-4640 [Abstract] [Full Text]  
• Fletcher, S., Bain, B. (2007). Eosinophilic leukaemia. Br Med Bull 0: ldm008v1-13 [Abstract] [Full Text]  
• Buitenhuis, M., Verhagen, L. P., Cools, J., Coffer, P. J. (2007). Molecular Mechanisms Underlying FIP1L1-PDGFRA-Mediated Myeloproliferation. Cancer Res. 67: 3759-3766 [Abstract] [Full Text]  
• Soverini, S., Iacobucci, I., Baccarani, M., Martinelli, G. (2007). Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. haematol 92: 437-439 [Full Text]  
• Fridman, J. S., Caulder, E., Hansbury, M., Liu, X., Yang, G., Wang, Q., Lo, Y., Zhou, B.-B., Pan, M., Thomas, S. M., Grandis, J. R., Zhuo, J., Yao, W., Newton, R. C., Friedman, S. M., Scherle, P. A., Vaddi, K. (2007). Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer. Clin. Cancer Res. 13: 1892-1902 [Abstract] [Full Text]  
• Sinai, P., Berg, R. E., Haynie, J. M., Egorin, M. J., Ilaria, R. L. Jr, Forman, J. (2007). Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo. J. Immunol. 178: 2028-2037 [Abstract] [Full Text]  
• Li, Z., Xu, M., Xing, S., Ho, W. T., Ishii, T., Li, Q., Fu, X., Zhao, Z. J. (2007). Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth. J. Biol. Chem. 282: 3428-3432 [Abstract] [Full Text]  
• Walz, C., Metzgeroth, G., Haferlach, C., Schmitt-Graeff, A., Fabarius, A., Hagen, V., Prummer, O., Rauh, S., Hehlmann, R., Hochhaus, A., Cross, N. C.P., Reiter, A. (2007). Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene. haematol 92: 163-169 [Abstract] [Full Text]  
• Rosati, R., La Starza, R., Barba, G., Gorello, P., Pierini, V., Matteucci, C., Roti, G., Crescenzi, B., Romoli, S., Aloisi, T., Aversa, F., Martelli, M. F., Mecucci, C. (2007). Cryptic chromosome 9q34 deletion generates TAF-I{alpha}/CAN and TAF-I{beta}/CAN fusion transcripts in acute myeloid leukemia. haematol 92: 232-235 [Abstract] [Full Text]  
• Lierman, E., Lahortiga, I., Van Miegroet, H., Mentens, N., Marynen, P., Cools, J. (2007). The ability of sorafenib to inhibit oncogenic PDGFR{beta} and FLT3 mutants and overcome resistance to other small molecule inhibitors. haematol 92: 27-34 [Abstract] [Full Text]  
• Steensma, D. P., Richard, R. E. (2007). Myeloproliferative disorders. ASH-SAP 2007: 172-227 [Full Text]  
• Campbell, P. J., Green, A. R. (2006). The Myeloproliferative Disorders. NEJM 355: 2452-2466 [Full Text]  
• Bumm, T. G.P., Elsea, C., Corbin, A. S., Loriaux, M., Sherbenou, D., Wood, L., Deininger, J., Silver, R. T., Druker, B. J., Deininger, M. W.N. (2006). Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease. Cancer Res. 66: 11156-11165 [Abstract] [Full Text]  
• Terrier, B., Piette, A.-M., Kerob, D., Cordoliani, F., Tancrede, E., Hamidou, L., Lebbe, C., Bletry, O., Kahn, J.-E. (2006). Superficial Venous Thrombophlebitis as the Initial Manifestation of Hypereosinophilic Syndrome: Study of the First 3 Cases. Arch Dermatol 142: 1606-1610 [Abstract] [Full Text]  
• Kulimova, E., Oelmann, E., Bisping, G., Kienast, J., Mesters, R. M., Schwable, J., Hilberg, F., Roth, G. J., Munzert, G., Stefanic, M., Steffen, B., Brandts, C., Muller-Tidow, C., Kolkmeyer, A., Buchner, T., Serve, H., Berdel, W. E. (2006). Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Molecular Cancer Therapeutics 5: 3105-3112 [Abstract] [Full Text]  
• Gavrilescu, L. C., Cross, N. C.P., Van Etten, R. A. (2006). Distinct Leukemogenic Activity and Imatinib Responsiveness of a BCR-PFGFR{alpha} Fusion Tyrosine Kinase.. ASH ANNUAL MEETING ABSTRACTS 108: 3634-3634 [Abstract]  
• Corless, C. L., Harrell, P., Lacouture, M., Bainbridge, T., Le, C., Gatter, K., White, C. Jr, Granter, S., Heinrich, M. C. (2006). Allele-Specific Polymerase Chain Reaction for the Imatinib-Resistant KIT D816V and D816F Mutations in Mastocytosis and Acute Myelogenous Leukemia. J. Mol. Diagn. 8: 604-612 [Abstract] [Full Text]  
• Milton, D. T., Riely, G. J., Pao, W., Miller, V. A., Kris, M. G., Heelan, R. T. (2006). Molecular On/Off Switch. JCO 24: 4940-4942 [Full Text]  
• Steensma, D. P. (2006). JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J. Mol. Diagn. 8: 397-411 [Abstract] [Full Text]  
• Akin, C. (2006). Molecular Diagnosis of Mast Cell Disorders: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J. Mol. Diagn. 8: 412-419 [Abstract] [Full Text]  
• Leiferman, K. M., Peters, M. S. (2006). Reflections on Eosinophils and Flame Figures: Where There's Smoke There's Not Necessarily Wells Syndrome.. Arch Dermatol 142: 1215-1218 [Full Text]  
• Alvarez, R. H., Kantarjian, H. M., Cortes, J. E. (2006). Biology of Platelet-Derived Growth Factor and Its Involvement in Disease. Mayo Clin Proc. 81: 1241-1257 [Abstract] [Full Text]  
• von Bubnoff, N., Manley, P. W., Mestan, J., Sanger, J., Peschel, C., Duyster, J. (2006). Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108: 1328-1333 [Abstract] [Full Text]  
• Lierman, E., Folens, C., Stover, E. H., Mentens, N., Van Miegroet, H., Scheers, W., Boogaerts, M., Vandenberghe, P., Marynen, P., Cools, J. (2006). Sorafenib is a potent inhibitor of FIP1L1-PDGFR{alpha} and the imatinib-resistant FIP1L1-PDGFR{alpha} T674I mutant. Blood 108: 1374-1376 [Abstract] [Full Text]  
• Thomas, R. K., Weir, B., Meyerson, M. (2006). Genomic approaches to lung cancer.. Clin. Cancer Res. 12: 4384s-4391s [Abstract] [Full Text]  
• Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., Akin, C. (2006). Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286-291 [Abstract] [Full Text]  
• Bellanne-Chantelot, C., Chaumarel, I., Labopin, M., Bellanger, F., Barbu, V., De Toma, C., Delhommeau, F., Casadevall, N., Vainchenker, W., Thomas, G., Najman, A. (2006). Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108: 346-352 [Abstract] [Full Text]  
• Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M. A., Iyer, V., Chen, T.-T., Huang, F., Decillis, A. P., Sawyers, C. L. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.. NEJM 354: 2531-2541 [Abstract] [Full Text]  
• Robert, C., Delva, L., Balitrand, N., Nahajevszky, S., Masszi, T., Chomienne, C., Papp, B. (2006). Apoptosis Induction by Retinoids in Eosinophilic Leukemia Cells: Implication of Retinoic Acid Receptor-{alpha} Signaling in All-Trans-Retinoic Acid Hypersensitivity.. Cancer Res. 66: 6336-6344 [Abstract] [Full Text]  
• von Bubnoff, N., Gorantla, S. P., Thone, S., Peschel, C., Duyster, J., Stover, E. H., Cools, J., Gilliland, D. G. (2006). The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 107: 4970-4972 [Full Text]  
• Goss, V. L., Lee, K. A., Moritz, A., Nardone, J., Spek, E. J., MacNeill, J., Rush, J., Comb, M. J., Polakiewicz, R. D. (2006). A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 107: 4888-4897 [Abstract] [Full Text]  
• Stover, E. H., Chen, J., Folens, C., Lee, B. H., Mentens, N., Marynen, P., Williams, I. R., Gilliland, D. G., Cools, J. (2006). Activation of FIP1L1-PDGFR{alpha} requires disruption of the juxtamembrane domain of PDGFR{alpha} and is FIP1L1-independent. Proc. Natl. Acad. Sci. USA 103: 8078-8083 [Abstract] [Full Text]  
• Gorska, M. M., Cen, O., Liang, Q., Stafford, S. J., Alam, R. (2006). Differential Regulation of Interleukin 5-stimulated Signaling Pathways by Dynamin. J. Biol. Chem. 281: 14429-14439 [Abstract] [Full Text]  
• Chung, R. T., Iafrate, A. J., Amrein, P. C., Sahani, D. V., Misdraji, J. (2006). Case 15-2006 -- A 46-Year-Old Woman with Sudden Onset of Abdominal Distention. NEJM 354: 2166-2175 [Full Text]  
• Yamada, Y., Rothenberg, M. E., Lee, A. W., Akei, H. S., Brandt, E. B., Williams, D. A., Cancelas, J. A. (2006). The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107: 4071-4079 [Abstract] [Full Text]  
• Prenen, H., Cools, J., Mentens, N., Folens, C., Sciot, R., Schoffski, P., Van Oosterom, A., Marynen, P., Debiec-Rychter, M. (2006). Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate. Clin. Cancer Res. 12: 2622-2627 [Abstract] [Full Text]  
• Becher, O. J., Holland, E. C., Sausville, E. A., Burger, A. M. (2006). Genetically Engineered Models Have Advantages over Xenografts for Preclinical Studies.. Cancer Res. 66: 3355-3359 [Abstract] [Full Text]  
• Tefferi, A., Elliott, M. A., Pardanani, A. (2006). Atypical Myeloproliferative Disorders: Diagnosis and Management. Mayo Clin Proc. 81: 553-563 [Abstract] [Full Text]